Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Read this before you consider it
The shift from injectable forms to an oral formulation marks a significant advancement addressing one of the major barriers in diabetes care, needle aversion
Reasons for switching may include: Side effects Inadequate response Coverage changes Availability Medical changes Patient preference Switching requires a clinician-directed plan
Zvenyach said the CMS Innovation Center, which studies health care payment models, also may be looking at whether it can create a pilot program to test the idea of having Medicare cover GLP-1 medications
US$ 22.31
US$ 20.69
US$ 20.15
